Here are the Form 4 insider transactions from Monopar Therapeutics Inc. (MNPR) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MNPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNPR filings page.
Monopar Therapeutics director Raymond Anderson exercised stock options covering 1,402 shares at $29.9986 and 1,740 shares at $30.00 on November 2, 2026. He also sold 3,142 common shares in four reported transactions: 840 at a weighted-average $66.16, 600 at $67.06, 200 at $68.68 and 1,502 at $70.04. The transactions were reported under a Rule 10b5-1 plan executed May 26, 2026.
Monopar Therapeutics (MNPR) director Kim R. Tsuchimoto reported option exercises and common-stock sales on November 2 and November 4, 2026. On November 2, she exercised options for 1,199 shares at $30 per share and sold 1,199 shares at a weighted-average price of $70.10 per share. On November 4, she exercised options for 856 shares at $30 and 2,035 shares at $14, and reported sales of 1,295 shares at a weighted-average $70.75, 996 shares at a weighted-average $71.35, and 600 shares at $72.21 per share.
All reported transactions were effected pursuant to a Rule 10b5-1 plan executed May 27, 2026. Separately, the filing lists 11,486 shares held by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Monopar Therapeutics (MNPR) reports that CEO and director Chandler Robinson had 597 common shares withheld by the issuer on October 20, 2026, to pay applicable withholding tax. The additional withholding was due to an administrative error in connection with the vesting and settlement of 12,873 restricted stock units on June 30, 2026. Robinson’s reported direct holdings after the transaction were 104,127 shares. The Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020, was separately reported as holding 62,815 shares indirectly.
Monopar Therapeutics (MNPR) director Christopher M. Starr exercised stock options for 8,400 common shares at $0.005 per share on October 1, 2026, and sold 8,400 shares in three transactions: 4,631 at a weighted average price of $78.09, 2,970 at $78.82, and 799 at $79.67. The respective sale prices ranged from $77.50 to $78.49, $78.50 to $79.49, and $79.50 to $80.01, inclusive. The transactions were effected pursuant to a Rule 10b5-1 Plan executed May 28, 2026. The reported positions following the transactions include 8,400 stock options and 9,880 common shares held by the Christopher M. Starr and Sheri L. Starr Revocable Trust, for which Starr serves as trustee.
Monopar Therapeutics (MNPR) Chief Operating Officer Andrew Cittadine had 4,384 restricted stock units vest and settle on September 30, 2026, resulting in 4,384 common shares. The issuer withheld 1,944 common shares to pay applicable withholding tax at $79.67 per share. His reported post-transaction restricted stock unit balance was 35,115 units.
Monopar Therapeutics Chief Executive Officer Chandler Robinson reported 9,801 restricted stock units surrendered for 9,801 common shares upon vesting and settlement on September 30, 2026. The issuer withheld 4,344 shares at $79.67 per share for withholding taxes. His reported post-transaction balance was 83,602 restricted stock units; the filing also lists 62,815 common shares held by the Chandler D. Robinson Irrevocable Trust. No Rule 10b5-1 plan is reported.
Monopar Therapeutics Chief Financial Officer Quan Anh Vu reported vesting and settlement of 614 restricted stock units on September 30, 2026, for 614 common shares. The issuer withheld 180 shares to pay applicable withholding tax at $79.67 per share. A total of 7,984 restricted stock units remained after the transaction; the original award was 9,826 restricted stock units granted December 2, 2025.
Monopar Therapeutics Chief Executive Officer Chandler Robinson exercised options for 14,056 common shares at $30 per share and 15,000 at $14 per share on September 24, 2026. He also sold 10,450, 9,638, 8,368 and 600 shares at weighted average prices of $87.15, $87.96, $88.97 and $89.79 per share, respectively, on that date. The transactions were effected under a Rule 10b5-1 Plan executed June 25, 2026. The report also lists 62,815 shares held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
Monopar Therapeutics (MNPR) director Kim R. Tsuchimoto reported an amended set of transactions on August 26, 2026, correcting a prior Form 4. The director exercised stock options for 2,055 shares at an exercise price of $30.00 and 2,035 shares at $14.00, receiving an equal number of common shares. On the same date, a total of 4,090 common shares were sold in multiple trades at weighted average prices between $108.83 and $113.84 per share, with underlying trade ranges from $108.07 to $114.34. All option exercises and sales were effected pursuant to a Rule 10b5-1 Plan executed on May 27, 2026. Following these transactions, 11,486 shares are reported as held indirectly by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Monopar Therapeutics (MNPR) director Raymond Anderson amended a prior insider report to include previously omitted option exercises and to reflect Monopar’s 5-for-1 reverse stock split effective August 12, 2024. On August 25, 2026, he exercised options for 3,142 shares of common stock at a $30.00 exercise price and sold 3,142 shares in three open-market transactions at weighted average prices of $110.04, $111.07, and $113.05. All transactions were effected under a Rule 10b5-1 trading plan executed on May 26, 2026.
Monopar Therapeutics (MNPR) reported that Acting Chief Medical Officer Patrice Rioux exercised 1,380 Stock Options for Common Stock on 2026-08-26 at an exercise price of $0.005 per share, converting them into 1,380 Common Shares. On the same date, 1 Common Share was sold at $111.26 per share. The option exercise exhausted this particular option grant, leaving 0 derivative shares reported as remaining from it. These transactions were effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
Monopar Therapeutics (MNPR) director Tsuchimoto Kim R reported multiple open-market sales of common stock. On August 26, 2026, the reporting person sold a total of 4,090 shares of Monopar common stock in six transactions, each reported at a weighted average price between $108.83 and $113.84 per share. The trades were effected pursuant to a Rule 10b5-1 Plan executed on May 27, 2026, and each sale was executed through multiple trades within disclosed price ranges.
Monopar Therapeutics (MNPR) director Raymond Anderson reported selling a total of 3,142 shares of common stock on August 25, 2026 in three open-market transactions under a Rule 10b5-1 trading plan executed on May 26, 2026. The reported per-share prices are weighted averages for shares sold across disclosed price ranges.
Monopar Therapeutics’ Chief Financial Officer Vu Quan Anh reported routine equity compensation activity tied to restricted stock units. On the vesting date, 1,228 restricted stock units converted into the same number of common shares. The company withheld 507 shares to cover tax obligations, a non‑market disposition.
Following these transactions, Vu Quan Anh directly holds 2,221 shares of common stock. He also retains 8,598 unvested restricted stock units from a 9,826-unit grant awarded on December 2, 2025, which began vesting on June 30, 2026 and is scheduled to fully vest by December 31, 2029.
Monopar Therapeutics Chief Executive Officer Chandler Robinson reported compensation-related stock activity. On June 30, 2026, 12,873 restricted stock units vested and settled into the same number of common shares. The issuer withheld 4,084 shares at $92.59 per share to cover applicable tax obligations.
Following these transactions, Robinson holds 99,267 shares of Monopar common stock directly and 62,815 shares indirectly through the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. The filing reflects routine RSU vesting and associated tax-withholding dispositions, not open-market purchases or sales.
Monopar Therapeutics Chief Operating Officer Andrew Cittadine exercised and settled 5,254 restricted stock units on June 30, 2026, receiving 5,254 shares of common stock. 2,309 shares were withheld by the company at $92.59 per share to cover withholding taxes. Following these transactions, he directly owns 55,614 shares of Monopar common stock. The restricted stock units come from multi-year grants that vest in quarterly installments through December 2029.
Monopar Therapeutics director Nicole Sweeny received a grant of stock options, acquiring rights to 1,284 shares of common stock. The options have an exercise price of $87.68 per share and expire on June 26, 2036.
The grant vests in two equal installments, with 50% vesting on September 30, 2026 and the remaining 50% vesting on December 31, 2026. Following this grant, Sweeny holds options on 1,284 shares directly. This is a compensation-related award rather than an open-market stock purchase or sale.
Monopar Therapeutics Chief Executive Officer Chandler Robinson reported routine equity compensation activity. On March 31, 2026, 6,732 restricted stock units vested and were settled into an equal number of common shares at an exercise price of $0.00 per share.
Of these shares, 1,972 were withheld by the issuer at $54.79 per share to cover applicable tax withholding obligations. Following these transactions, Robinson held 90,478 shares of common stock directly and 62,815 shares indirectly through the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
Monopar Therapeutics Chief Operating Officer Andrew Cittadine increased his direct equity stake through RSU vesting. On March 31, 2026, 3,514 restricted stock units vested and were settled into an equal number of common shares at a conversion price of $0.00 per share.
To cover withholding taxes on this vesting, 1,571 common shares were withheld by the company at a value of $54.79 per share, rather than sold in the open market. After these transactions, Cittadine directly owned 52,669 shares of Monopar Therapeutics common stock.
Rodriguez Susan reported acquisition or exercise transactions in this Form 4 filing.
Monopar Therapeutics granted Chief Clinical Science Officer Susan Rodriguez stock options covering 48,728 shares on March 2, 2026. The options were reported at a price of $0.0000 per share and are held directly.
According to the vesting terms, 6/48ths of the options vest on September 2, 2026, with the remaining 1/48th vesting each month thereafter. After this grant, Rodriguez was reported as holding 48,728 stock options in total.
Monopar Therapeutics Chief Executive Officer and director Chandler Robinson reported an indirect acquisition of 62,815 shares of common stock on a Form 4. The shares were received at $0 per share through a pro rata liquidating distribution from Tactic Pharma, LLC and are held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. Following this transaction, Robinson also reports 85,718 common shares held directly.
Monopar Therapeutics director reports indirect share distribution. A reporting person who serves as a director of Monopar Therapeutics disclosed an indirect disposition of 43,499 shares of common stock on 12/16/2025 at a stated price of $0 per share, coded as transaction type "J" (other). The filing explains this relates to a pro rata distribution of Monopar shares by Gem Pharmaceuticals, LLC to its members, in which the reporting person states they have no pecuniary interest.
After the transaction, the reporting person reports 567,580 Monopar shares held indirectly through Gem and 93,750 shares held by DMH Business LLC. As a manager of Gem and of DMH Business LLC’s controlling owner, the reporting person may be deemed to share voting and dispositive power over these shares but disclaims beneficial ownership except to the extent of any pecuniary interest.
Monopar Therapeutics director reported receiving additional company shares in an insider transaction. On 12/16/2025, the reporting person acquired 7,710 shares of Monopar Therapeutics common stock at a stated price of $0, coded as transaction type J. After this transaction, the reporting person beneficially owned 13,883 shares, held directly.
According to the explanation provided, the shares were received through a pro rata distribution from Gem Pharmaceuticals, LLC, in which the reporting person is a non-managing member. The filing indicates it was submitted for one reporting person in their capacity as a director of Monopar Therapeutics.